Firstly, miR-218 inhibits the expression of the target gene inhibitor of nuclear factor κB (NF-κB) kinase β, and in a dose-dependent manner, inhibits the expression of NF-κB, whilst reducing the expression of matrix metalloproteinase (MMP) 9 and inhibiting the invasion and migration ability of glioma cells (12). This evidence concerns the gene NFKB1 and glioma.